Lescarden

Lescarden is a biotechnology company focused on the development and commercialization of biological products derived from bovine tracheal cartilage (BTC). The company's flagship product, Catrix, is a proprietary processed bovine cartilage powder used primarily for wound management, including the treatment of chronic wounds like diabetic ulcers and pressure sores. Beyond wound care, Lescarden has explored the therapeutic potential of BTC in inflammatory conditions such as osteoarthritis and psoriasis, as well as its anti-angiogenic properties in oncology. The company's research is based on the work of founder Dr. John F. Prudden, who identified the regenerative and anti-inflammatory properties of cartilage-derived substances. Lescarden operates as a publicly traded entity and markets its products to healthcare providers and through various distribution channels. The company continues to maintain its intellectual property and product portfolio within the regenerative medicine space.